ZIOPHARM Oncology (NASDAQ:ZIOP)‘s stock had its “hold” rating reaffirmed by Zacks Investment Research in a research note issued on Saturday.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other brokerages have also recently commented on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright restated a “buy” rating and set a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Finally, Raymond James Financial reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $12.67.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) traded up $0.10 on Friday, reaching $4.36. 1,311,411 shares of the company traded hands, compared to its average volume of 1,734,040. ZIOPHARM Oncology has a fifty-two week low of $3.77 and a fifty-two week high of $7.88. The firm has a market capitalization of $604.76, a PE ratio of -8.38 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. During the same quarter in the previous year, the company posted ($0.11) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts forecast that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.

In other news, CEO Laurence James Neil Cooper purchased 6,440 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the completion of the transaction, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 10.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in ZIOPHARM Oncology by 7.6% during the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after acquiring an additional 553,933 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in ZIOPHARM Oncology during the third quarter worth $746,000. Steward Partners Investment Advisory LLC bought a new stake in ZIOPHARM Oncology during the third quarter worth $145,000. Tudor Investment Corp ET AL raised its position in ZIOPHARM Oncology by 390.4% during the second quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 50,395 shares in the last quarter. Finally, Northern Trust Corp raised its position in ZIOPHARM Oncology by 10.1% during the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after acquiring an additional 149,067 shares in the last quarter. 40.23% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/13/ziopharm-oncology-ziop-stock-rating-reaffirmed-by-zacks-investment-research.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.